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ABSTRACT: Microbubbles (MBs) are widely used as contrast enhancement
agents for ultrasound imaging and have the potential to enhance therapeutic
delivery to diseases such as cancer. Yet, they are only stable in solution for a
few hours to days after production, which limits their potential application.
Freeze-drying provides long-term storage, ease of transport, and consistency in
structure and composition, thereby facilitating their use in clinical settings.
Therapeutic microbubbles (thMBs) consisting of MBs with attached
therapeutic payload potentially face even greater issues for production,
stability, and well-defined drug delivery. The ability to freeze-dry thMBs
represents an important step for their translation to the clinic. Here, we show
that it is possible to freeze-dry and reconstitute thMBs that consist of lipid-
coated MBs with an attached liposomal payload. The thMBs were produced
microfluidically, and the liposomes contained either calcein, as a model drug,
or gemcitabine. The results show that drug-loaded thMBs can be freeze-dried
and stored for at least 6 months. Upon reconstitution, they maintain their structural integrity and drug loading. Furthermore, we
show that their in vivo echogenicity is maintained post-freeze-drying. Depending on the gas used in the original bubbles, we also
demonstrate that the approach provides a method to exchange the gas core to allow the formulation of thMBs with different gases
for combination therapies or improved drug efficacy. Importantly, this work provides an important route for the facile off-site
production of thMBs that can be reformulated at the point of care.
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1. INTRODUCTION
Microbubbles (MBs) are widely used as contrast enhancement
agents in ultrasound (US) imaging and typically consist of a
perfluorocarbon gas core and a biocompatible shell (e.g.,
protein, phospholipid, or polymer).1−4 The enhanced US
contrast arises from the high mismatch in acoustic impedance
between the gas core and the surrounding medium. The
properties of the shell and the encapsulated gas affect the MB
stability in vitro and in vivo as well as their US response.5−10
MBs undergo US-induced oscillations that result in micro-
streaming, or at higher amplitude, MB destruction.11,12 These
processes can create pores in cell membranes and enhance the
passage of drug molecules across the cell membrane. These
characteristics mean that drugs co-delivered with MBs and
exposed to focused US can promote localized and enhanced
therapeutic delivery.2,13,14 Furthermore, it has been demon-
strated that it is possible to attach drug-filled liposomes, oil
nanodroplets, genes, or lipid conjugated drugs to the shell of
MBs,15−19 leading to the formulation of therapeutic micro-
bubbles (thMBs). The thMB complex can be further targeted
toward the required delivery site using antibodies, or other
targeting ligands, for localized delivery.20
Typically, for safe use in vivo, MBs should have a size no
more than 10 μm in diameter. There are numerous preparation
protocols for MBs that provide control over the size
distributions that can be achieved.21,22 Sonication and
mechanical agitation are the conventional methods for
producing MBs at a high concentration of ∼109−1010 MB/
mL but have poor control over the MB size.23,24 A flow-
focused microfluidic (MF) technology has been successful for
the production of monodisperse MBs with size control in a
range of 2−50 μm. However, these MBs are susceptible to
changes in size off-chip and are produced at relatively low
concentrations (∼106−108 MB/mL).25−28 We have previously
developed a rapid pressure drop on-chip method, which led to
the production of MB populations with a size distribution in
the range 0.5−3 μm as well as a “one-pot” MF production of
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liposome-loaded MBs at high concentrations (∼109 MB/
mL).6,29
The in vitro and in vivo stability of MBs has been extensively
studied by different groups, and the role of the gas type, lipid
shell composition, and saturation have all been shown to be
important for controlling MB lifetime.6,9,30−33 Although MBs
can often be stable for many hours at 4 °C, this is still relatively
short for therapeutic agents and generally means that treatment
protocols would require MB production directly before use, at
the point of care. If thMBs could be freeze-dried (FD) at
production and subsequently reconstituted at the point of use,
this would offer advantages of better control of drug/MB
concentration and simpler protocols for administration and
would also allow off-site production at lower cost.
FD has been widely used for increasing shelf life, preserving
sensitive samples such as vaccines and proteins, stabilizing
pharmaceutical products such as liposomes, and maintaining
biological activities after reconstitution.34−38 FD has been used
as a method for drug loading preformulated microparticles,
ensuring uniform and high drug loading.39 Although the FD
process is relatively simple, ensuring that the reconstituted
product is the same form as the starting one is critical. To this
end, sugars are frequently used as cryoprotectants. They work
by forming a glassy layer around individual particles,
preventing interaction between them and creating a protective
barrier from the mechanical stresses exerted by the formation
of ice crystals.40 Glucose, sucrose, trehalose, and mannitol have
been widely used.38 It has been shown that sucrose and lactose
are better protectants for systems involving lipid layers, where
they form a glassy layer near the polar head groups, on the
inside and outside of the liposomes, that protects the lipid
bilayer from collapse under the stress caused by the FD
process.41
A vitrification theory is the leading explanation for how
cryoprotectants work, and as explained by Franks,36 freezing
and drying should occur below the glass transition temperature
Tg to avoid the collapse of the structure. Freezing is the first
step in the process where most of the water is removed from
the solution as ice crystals begin to form. The methods of
freezing vary, either by using liquid nitrogen to flash freeze the
sample42 or by cooling the sample within an FD machine at a
steady cooling profile of 1 °C/min.36 As the water is removed,
the concentration of the cryoprotectant increases and the
solution becomes increasingly viscous. This is then followed by
drying under vacuum at a temperature below Tg, where the
sublimation of ice from the sample takes place.
Freeze-drying has been used for the preparation of MBs for
contrast-enhanced US imaging. SonoVue, a clinically used
contrast agent produced by Bracco, uses freeze-drying or spray-
drying of lipids, which are subsequently mechanically agitated
in the presence of a low solubility gas and aqueous carrier to
create MBs with a size of 0.5−10 μm just before use.43
Sonozoid, produced by GE Healthcare, uses sucrose during the
lyophilization of lipid-coated perfluorobutane microspheres,
which are reconstituted by manual mixing.44,45 The method
was patented by Borden in 2010 for freeze-drying in-house-
produced MBs as a method for possible gas-core exchange.46
The freeze-drying concept has also been applied to MBs in the
presence of cryoprotectants such as sucrose, where the bubbles
were found to form cavities in the cryoprotectant matrix. After
refilling the vial with the appropriate gas, these cavities are
filled and MBs are released upon rehydration. This has been
used by Wheatley’s group in surfactant-based contrast agents
(such as SE61, composed of Span60 and water-soluble vitamin
E) to change the octa-fluoropropane gas core to O2 to increase
the O2 level in hypoxic tissue upon delivery
47 and, by the same
group, to preserve the integrity of contrast agents with the non-
ionic ST68.42 The freeze-drying process has also been
employed to increase the shelf life of polymeric MBs. In this
study, they demonstrated that sucrose was better than glucose
and other cryoprotectants for rhodamine-B dye loading into
the polymeric MBs with all of the dye being retained after
lyophilization with no leakage in the aqueous suspension.48
In 2019, Unga et al. freeze-dried octa-fluoropropane lipid-
based MBs and claimed that a modified composition of
DSPC:DSPG:DSPE-PEG2000 formulated MBs with sucrose
was a versatile formulation for improved stability of MBs after
freeze-drying.49 They also examined scaling up the production
process in-line with potential clinical applications and saw no
changes in composition or toxicity of the MBs after 1 year of
storage.50 However, to date, the freeze-drying of drug-loaded
thMBs has not been reported and the potential for loss of
liposomes from the MB shell and/or leakage of liposomal
content must be considered.
Here, we investigate the feasibility of freeze-drying and
reconstituting thMBs, i.e., MBs loaded with liposomal payloads
(Scheme 1). We evaluate the quality of MBs reconstituted up
to 6 months post-FD and test MB stability and lifetime both in
vitro and in vivo. The FD process not only provides a long shelf
Scheme 1. Process of Freeze-Drying Microspray thMBsa
aThe thMBs are freeze-dried as shown schematically in (a) and can be stored until required. (b) The thMBs can be reconstituted with the same gas
core or with a different one as required. The image in (c) shows the freeze-dried thMB powder.
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life and facilitates easy shipping of thMB products but also
provides the ability to control the MB concentration of the
reconstituted population and the possibility to exchange the
encapsulated gas after the FD process. This is considered a
vital step toward translation of thMBs from the lab toward
clinical trials and commercialization.
2. MATERIALS AND METHODS




choline (DSPC), and cholesterol, were purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Texas Red 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine and triethylammonium salt (DHPE-
Texas red) were purchased from Invitrogen Life Technologies Ltd.
(Paisley, UK). Stock solutions of lipids were prepared by dissolving
the powder lipids as received in 50/50 chloroform/methanol. The
biotin-binding protein NeutrAvidin was purchased from Life
Technologies (Paisley, UK). Tetradecafluorohexane (C6F14, 99%
purity), cobalt(II) chloride (CoCl2, >98% purity), gemcitabine
hydrochloride (>98% purity), NaCl, sucrose, and glucose were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Calcein and
Triton X-100 were purchased from Fisher Scientific (Fisher Scientific
UK Ltd., UK).
2.2. Microbubble Production and Characterization. A
Horizon instrument (Horizon v3, Leeds, UK)29 was used for all
MB production with a polymethylmethacrylate (PMMA) flow-
focused MF chip designed in-house and fabricated by Epigem
(Redcar, UK) to prepare MBs according to methodologies previously
published.29,51 Both the liquid flow rate and gas (perfluorobutane
(C4F10) from F2 chemicals (Preston, UK)) pressure were controlled
by a p-pump, a pressure-based pumping system from Dolomite
(Royston, UK).
Liposomes were produced with different encapsulations, such as
calcein as a fluorescent model drug as well as chemotherapy drugs
such as gemcitabine (gem.) and SN38. These were manufactured by
extruding a phospholipid solution through a polycarbonate membrane
using an Avanti mini extruder (Alabaster, AL, USA).12,15 Briefly, a
mixture of DSPC, cholesterol, and DSPE-B-PEG2000 was dissolved
together and mixed in the ratio 60:35:5 mol %, respectively.
Chloroform was evaporated under vacuum for ∼24 h, after which
the lipids were re-suspended in a suitable buffer solution, depending
on the encapsulant. The homogeneous solution was then extruded at
60 °C through a 400 nm membrane seven times and then through a
200 nm membrane 21 times. The liposomes were then cleaned either
by centrifugation at 90Kg at 4 °C for 60 min in the case of calcein and
gem. to remove un-encapsulated drug or by filtration through a 200
nm membrane in the case of SN38 liposomes.
Liposome size distribution and concentration were measured on a
NanoSight NS300 (Malvern Panalytical, UK). The liposome sample
was diluted 100,000× in PBS, and the measurement was made at 25
°C. For each sample, three 60 s videos were captured.
MBs were prepared as previously described.6 Briefly, DPPC and
DSPE-B-PEG2000 were mixed together at 95:5 mol %, respectively.
After evaporation of the chloroform, the lipids were re-suspended in
MilliQ water containing 1% glycerol, 10% sucrose, and 4 mg/mL
NaCl in a ∼1 mL vial using an ultrasonic bath for about 1 h. A total of
10 μL of C6F14 was added to the homogeneous solutions prior to use
in the Horizon (MB maker).6
ThMBs were prepared using the “one-pot” production method
previously described,12,26 in which 100 μL of the premade liposomal
solution containing ∼1 × 1011 liposomes was incubated with 5 μL of
42 M stock NeutrAvidin for 20 min. The liposomal mix was then
incubated with the MB phospholipid solution containing the 10%
sucrose used to prepare the MBs for further 20 min, after which C6F14
was added and thMBs were prepared with the Horizon platform.
After preparation of MBs or thMBs, the sample was flash frozen in
liquid nitrogen for 20 min. The samples were subsequently placed in a
mini-Lyotrap bench top freeze dryer (LTE Scientific Ltd., Oldham,
UK), which was pre-cooled to −55 °C and was maintained under
vacuum at 9 × 10−3 mBar for 48 h. The process is shown
schematically in Scheme 1. After freeze-drying, the vials were sealed
under vacuum and stored at 4 °C. The image in Scheme 1c shows the
typical powdery appearance of the lyophilized thMB sample.
To re-suspend the freeze-dried sample, the head space of the vial
was filled with C4F10 gas for 3 min at 700 mbar gas pressure.
Typically, 1 mL of buffer was then added and the solution was gently
shaken by hand until the dried cake of MBs was fully reconstituted
(Scheme 1b).
For each MB population formed, a 10 μL sample was diluted 10-
fold to facilitate counting and sizing of the MBs. A total of 30 μL of
this MB solution was collected from the middle of the homogeneous
sample and introduced in a 50 μm height chamber on a glass slide.
The MBs were allowed to rise for ∼1 min before images were
acquired. An inverted microscope (Nikon, Japan) was used to image
the MBs on a 60× magnification, and images were captured using a
CCD camera (DS-Fil 5 Mpixel, Nikon, Japan). Twenty images for
each sample were taken from random locations across the chamber,
and the concentration and size distribution were obtained using a
custom MATLAB (MathWorks, US) script utilizing the Image
Analysis Toolbox.52
2.3. Long-Term Stability of the Freeze-Dried MBs and In
Vitro and In Vivo Stability of the Reconstitutes. For studies of
the long-term stability of MBs, freeze-dried samples were stored in
sealed vials at 4 °C, and a sample was examined every month for 6
months. For each sample, MBs were reconstituted and their
concentration and size distribution were determined.
To determine the time frame for using MBs after reconstitution,
the in vitro stability of the reconstituted MBs was tested by counting
MB number and size every 15 min from a vial of MBs kept at room
temperature.
The in vivo stability/lifetime of the MBs and gem.-loaded thMBs
was tested as previously described.6 CD1 nude male mice aged 7−9
weeks (Charles River Laboratories) were housed in individually
ventilated cages with free access to food and water. All experiments
were performed following local ethical approval and in accordance
with the Home Office Animals (Scientific Procedures) Act 1986. Mice
were anaesthetized using isofluorane, and a 27-gauge tail vein catheter
was inserted. The aorta and inferior vena cava were imaged using a
RMV 704 transducer (40 MHz) attached to a Vevo 770 high-
frequency ultrasound machine (FUJIFILM VisualSonics). Pulse Wave
Doppler imaging was used to confirm the pulsatile flow in the aorta. A
syringe driver was used to inject 3 × 107 MBs in 100 μL volume at 0.6
mL/minute. Cine loops of the injection and for the next 15 min with
1 min gaps between each cine loop were recorded in contrast mode at
50% power.
2.4. Drug Leakage Assay. Calcein-loaded liposomes were used
to test drug leakage from liposomes post-reconstitution. The calcein
was encapsulated at 0.5 mM, a concentration at which it is fluorescent.
CoCl2 was used as a quencher that does not cross the membrane but
will quench fluorescence from any calcein that has leached into the
bulk solution surrounding the liposomes.53
A Spectramax M2e microplate reader set with excitation/emission
wavelengths of calcein 495/515 nm was used to measure the
fluorescence intensity using a 96-well opaque plate. Three groups of
MBs loaded with calcein liposomes were tested: one without any
CoCl2 in the bulk solution to measure the intensity of encapsulated
calcein, the second had CoCl2 and 50 μL of ethanol to damage the
liposome membrane and release the encapsulated calcein, and the
third with CoCl2 only to quench any leaked calcein in the bulk
solution over time. Samples were tested every 30 min for 3 h. Each of
these groups was analyzed in triplicate at each time point using
samples before and after freeze-drying and repeated three times with
three different samples.
2.5. Gas Exchange. MBs with C4F10 or SF6 (BOC, UK) gas cores
were prepared microfluidically and FD as described above. Post-FD, it
was possible to reconstitute the MBs with different gaseous cores. As
an example, oxygen was used to fill the head space of the vial before
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adding the hydrating solution and reconstituting the MBs. O2 release
from reconstituted MBs was tested using an O2 dipping probe
(PreSens Precision Sensing GmbH, Regensburg, Germany) and
compared to the release profile from freshly prepared O2 MBs. For O2
reconstitution, the lipid shell consisted of DSPC and DSPE-PEG2000
at 95:5 mol % at a final lipid concentration of 5 mg/mL. The oxygen
release profile was performed by placing the oxygen probe in 5 mL of
MilliQ water with continuous stirring to attain a baseline for 1 min
before 250 μL of MBs was added.
3. RESULTS AND DISCUSSION
MBs were prepared using the 3D spray-regime MF chip as
previously described.6 This typically produces MBs with a
mean size of ∼2 μm at concentrations between 1 and 5 × 109
MB/mL. The addition of a therapeutic payload of liposomes
does not adversely affect the concentration or size. Liposomes
fluorescently labeled with Texas Red in the shell were loaded
with gem. and used to prepare gem. thMBs. The liposomes
were characterized using the Nanosight and typically were
around 180 nm in diameter (Figure S1). Figure 1a,b shows the
thMB size distribution, the inset is the bright field optical
image, and Figure 1b shows the fluorescence image of gem.-
loaded thMBs. Figure 1c,d shows the thMB size distribution
and images after reconstitution of the freeze-dried product.
When reconstituting back in 1 mL of buffer, there is typically a
small drop in MB concentration; however, this can be offset by
reconstitution into smaller volumes, which allow bubble
concentrations to be controlled. There is also a slight reduction
in the mean size of the MBs that results from the loss of the
larger sized bubbles. However, as shown from the histogram,
there is no shift in the whole population. Importantly,
liposomes both retain their fluorescence and remain attached
to the MBs post-reconstitution, as shown in the fluorescence
image (Figure 1d).
3.1. Long-Term Stability of Freeze-Dried MBs. The FD
aliquots were stored at 4 °C, and one aliquot was reconstituted
every month for 6 months to measure the MB concentration
and size distribution by optical microscopy (Figure 2).
There was a slight decrease in average concentration post-
FD for MBs and thMBs ((1.5 ± 0.7) × 109 to (9 ± 0.4) × 108
MB/mL) and also a small decrease in the mean diameter of
MBs and thMBs (2.3 ± 0.3 to 1.7 ± 0.1 μm). However, these
changes were not time-dependent over the period investigated,
suggesting that FD products were stable for at least 6 months
when stored at 4 °C. We note that there was no noticeable
difference between the MB and the thMB samples.
Post-reconstitution, the stability of the MB and thMB
samples was tested for up to 4 h in a closed vial at room
temperature and atmospheric pressure. Figure 3a,b shows both
MBs and thMBs showing no appreciable change in
Figure 1. Concentration and mean size of gem.-loaded thMBs before and after FD. (a and c) Histograms showing size distribution of gem.-loaded
thMBs (a) before with an average diameter of 2.1 ± 1.4 μm and a concentration of 1.5 ×109 and (c) after with an average diameter of 1.7 ± 0.7 μm
and a concentration of 9.4 × 108. The bright field microscopy inset shows MBs before and after FD (scale bar is 10 μm). (b and d) Fluorescence
image of thMBs with Texas Red fluorescently tagged gem. liposomes surrounding the thMBs before and after FD, respectively.
Figure 2. Long-term stability of MBs and liposome-loaded thMBs.
MB concentration and mean diameter are displayed as a function of
storage time (in the freeze-dried state). Error bars represent the
standard deviation for at least three independent batches of MBs.
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concentration or size, providing ample time for MBs to be used
post-reconstitution.
3.2. Drug Leakage Test. As a test of liposomal integrity,
calcein was loaded into liposomes at 0.5 mM, i.e., below the
self-quenching concentration (Figure S2). CoCl2 quenches
calcein fluorescence, and 100 μL of 1 mM CoCl2 was added to
the thMB solution post-formation to quench any un-
encapsulated or free calcein (Figure S3). The graph in Figure
4 shows that with thMBs formed via the conjugation of clean
liposomes (cleaned by centrifugation as explained in the
Materials and Methods section) to the MB shell, the addition
of CoCl2 to such solutions shows only a modest decrease in
fluorescence. The addition of ethanol led to the rupture of
liposomes and quenching of the fluorescence from the released
calcein when in the presence of CoCl2. This demonstrates that
not only do the liposomes remain attached to the MBs during
the FD process but that they also retain their payload.
The leakage of calcein from liposomes bound to MBs before
and after FD is presented in Figure S5, where the fluorescence
of the loaded MBs was tested over a 3 h period at room
temperature, either immediately following production or
following resuspension post-FD. These results show that
post-FD, there is a ∼15% decrease in fluorescence over the
subsequent 3 h.
In vivo testing of the US properties of both MB and gem.
thMB populations before and after FD was performed, and the
intensity vs time curves (TICs) were collected from three mice
in each case. These curves were assessed for contrast
enhancement and stability in the blood stream by imaging
the MBs in the aorta and the interior vena cava (highlighted
areas) in Figure 5. Echogenicity and stability of the groups
show no statistically significant differences in terms of peak
enhancement (contrast enhancement), wash-in slope (rate of
MB flow), time to peak enhancement, decay rate (reduction in
the contrast enhancement from the peak), area under the curve
(indicative of the total area perfused), and full width at half-
maximum (FWHM, the length of time at which the contrast
enhancement is 50% of the peak intensity or greater).
Therefore, there are no statistically significant differences in
in vivo imaging parameters or lifetime of the MBs.
3.3. Gas Exchange. A potential benefit of freeze-drying
MBs is that it offers a facile way to exchange the composition
of the gas core. By simply changing the gas head space during
reconstitution, it is possible to formulate MBs with a new gas
core. However, we have found that the ability to do this
depends on the gas used in the original MB formulation.
Figure 6 shows examples of forming O2 MBs post-FD from
samples where the original core gas was O2 (Figure 6a) or SF6
(Figure 6c). When the original core gas was C4F10, we were
able to reconstitute MBs (Figure 6b); however, in this case,
Figure 3. Stability of reconstituted (a) MBs and (b) thMBs. Concentration and size of the MB and thMB populations over 4 h at room
temperature. Open circles represent the concentration, and open squares represent the mean diameter.
Figure 4. Structural resilience of calcein-filled liposome-loaded MBs
to freeze-drying. (a) Schematic showing concept of the leakage assay.
(left) Calcein-loaded liposomes were attached to MBs. (middle)
CoCl2 was added to the supernatant to quench any fluorescence that
leaked from the liposomes. (right) Ethanol was used to break the lipid
membrane and release the fluorophore, which was quenched by the
surrounding CoCl2. (b) Graph showing the fluorescence from the
thMBs post-reconstitution (thMBs), with the addition of CoCl2
(thMBs + CoCl2) and following rupture with ethanol (thMBs +
CoCl2 + EtOH).
Figure 5. (a) High-frequency contrast-enhanced ultrasound image
showing the aorta and the interior vena cava post-injection with gem.-
thMBs (green-colored signal). (b) Ultrasound time−intensity curves
(TICs) in mouse aortas for MBs and gem.-thMBs before and after
freeze-drying.
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our data (discussed later) suggest that the core was not
exchanged and that the gas core remained predominantly
C4F10 post-reconstitution.
We note that MBs that had an original O2 core and were
then reconstituted in O2 were not stable after FD and the
concentration fell by a factor of two. To compensate for this,
the freeze-dried O2 MBs were usually re-hydrated in half the
original volume of solution. This was not seen for the other
MBs. It was noticed that oxygen-filled bubbles behave
differently from fluorocarbon bubbles, and in the case of
post-freeze-drying (Figure 6a), the bubble distribution consists
of two populations, the original sized MB plus some
corresponding to a larger, possibly merged MBs. This leads
to an apparent increase in average size to ∼3 μm. In some
cases, these also formed elliptical bubbles. However, this is not
the case for C4F10 and SF6 post-freeze-drying (Figure 6b,c)
where the size distribution did not show an observable
difference after FD. Figure 7 shows the increase in O2
concentration in water following the addition of the different
O2 MBs to MilliQ water. For controls, we also reconstituted
SF6 and C4F10 back to their original gas core. Upon addition of
these control MBs to a 5 mL water solution, there was no
notable change in O2 levels in the water.
However, MBs with original gas cores of O2 and SF6 could
be reconstituted with O2 post-freeze-drying, and this led to a
significant release of O2 into the aqueous solution with ∼3%
increase in O2 water saturation level. For the MBs with a C4F10
core but reconstituted with O2, we saw only a small increase in
oxygen saturation level post-reconstitution (<0.5%), indicating
that most of the MBs did not contain significant O2.
During the freeze-drying process, the bubbles are maintained
at −55 ° C under vacuum with an equivalent pressure of 9 ×
Figure 6.MBs prepared with different gas cores prior to freeze-drying (left) and following rehydration in the presence of oxygen post-freeze-drying
(right). Lipid constituents for MB production alongside MB concentration and size pre- and post-FD in the presence of O2 are shown. (panel a)
MBs prepared with oxygen core in a DSPC-dominated lipid shell and reconstituted after FD in oxygen gas. (panel b) MBs prepared with the C4F10
gas core and reconstituted after FD in the presence of oxygen gas. (panel c) MBs prepared with SF6 and reconstituted after FD in the presence of
oxygen gas.
Figure 7. (a) O2 release over time from MBs prepared with O2, C4F10, SF6 gas cores prior to freeze-drying and then reconstituted with different
gases post-freeze-drying in 5 mL of water. (b) Predicted vaporization temperature of MBs with different gas cores at −55 ° C and at 9 × 10−3 mBar,
representing conditions during the freeze-drying process.
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10−3 mBar. Using a model that we have described
previously,54,55 we predicted the vaporization temperature of
MBs of various sizes with commonly used gas cores under
these conditions. With a surface tension of 20 mN/m,6 SF6,
C3F8, and O2 MBs >1 μm in diameter would all remain
gaseous during freeze-drying. On the contrary, C4F10 MBs with
diameters of ≲1.4 μm would remain in a condensed, liquid
phase, close to the modal diameter of our MBs. These results
suggest that C4F10 largely remains in the FD MB “cake” such
that upon reconstitution, they return to being C4F10 MBs with
little O2 content. However, for C3F8 and SF6 MBs, the gas core
can easily be replaced with O2 after the freeze-drying process.
For all cases, a fixed volume of 250 μL of the MB solution
was added to 5 mL of water; however, the MB concentration
was higher in the case of FD SF6 and is in the order of FD SF6
> fresh O2 > FD O2 MBs, which was calculated to be averages
of 3.2 × 108, 1.4 × 108, and 6 × 107 MBs in 250 μL for each
case, respectively. This difference in MB concentrations is
clearly translated to the detected increase in water oxygen
concentration in Figure 7.
4. CONCLUSIONS
The widespread use of MBs as contrast-enhanced ultrasound
agents can be attributed to the ease with which samples can be
prepared, from a spray- or freeze-dried product and
reconstituted as required. However, this is not the case for
small-molecule drug-loaded thMBs.42,47,49,50 Here, we have
demonstrated that drug-loaded liposomes attached to MBs
(thMBs) can be freeze-dried and reconstituted without
adversely affecting either the attachment of the liposomes to
the MBs or causing leakage of the therapeutic agents from the
liposome. Fluorescence microscopy studies showed that the
thMBs were still coated with their liposomal payload, and
fluorescence leakage assays of a model drug showed that these
liposomes remained intact following reconstitution. The
freeze-dried thMB product is stable and can be reformulated
for time periods of at least 6 months. Furthermore, the stability
and echogenic properties of the drug-loaded MBs were
maintained in vivo after freeze-drying. Our approach allows
large-scale production and storage of thMBs, requiring only a
simple reconstitution step prior to use. Once reconstituted, the
thMBs have an on-bench lifetime of >4 h, giving ample time
for use. During the reconstitution, we found that as long as the
original thMB preparation was made using SF6, then it is
possible to exchange the gas core of the thMBs, e.g., to oxygen,
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